Recent News

• 02.09.2026 - Celldex to Present at Upcoming Investor Conferences
• 12.09.2025 - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
• 11.10.2025 - Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.10.2025 - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
• 11.07.2025 - Celldex to Present at Upcoming Investor Conferences

Recent Filings

• 02.09.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 144 Report of proposed sale of securities
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 144 Report of proposed sale of securities